Trimebutine base CAS: 39133-31-8

CAS NO: 39133-31-8
Trimebutine base
Chemical Name: Trimebutine
Molecular Formula: C22H29NO5
Formula Weight: 387.47
CAS No.: 39133-31-8
Description Review
Description

Trimebutine Base is a medication used to treat gastrointestinal disorders such as irritable bowel syndrome (IBS) and functional dyspepsia. It works by regulating the movement of the digestive tract and reducing symptoms such as abdominal pain, bloating, and constipation.

Chemical Name:

The chemical name of Trimebutine Base is (4-{[(4-methoxyphenyl)methyl]carbamoyl}-1-[(4-methylphenyl)sulfonyl]piperidine.

Molecular Formula:

The molecular formula of Trimebutine Base is C22H29N3O4S.

Formula Weight:

The formula weight of Trimebutine Base is 431.55 g/mol.

CAS No:

The CAS number of Trimebutine Base is 39133-31-8.

Top Ten Keywords from Google and Synonyms:

  1. Gastrointestinal medication
  2. Irritable bowel syndrome treatment
  3. Functional dyspepsia therapy
  4. Trimebutine
  5. Antispasmodic drug
  6. Bowel regulation medication
  7. Abdominal pain relief
  8. Digestive system stimulant
  9. Chronic constipation management
  10. Intestinal motility regulator

Synonyms: Trimébutine, Trimetobas, Trimbutin, Modulon, Debridat, Neobutin

Health Benefits of Trimebutine Base:

Trimebutine Base is primarily used to treat gastrointestinal disorders such as irritable bowel syndrome and functional dyspepsia. It helps in reducing symptoms such as abdominal pain, bloating, constipation, and diarrhea. Additionally, it can improve intestinal motility and regulate bowel movements.

Potential Effects:

Trimebutine Base is an antispasmodic medication that works by regulating the movement of the digestive tract. It reduces the strength and frequency of contractions in the intestine, which can help alleviate pain, bloating, and other symptoms associated with gastrointestinal disorders. It also stimulates the release of digestive enzymes, which can improve digestion.

Product Mechanism:

Trimebutine Base works by binding to specific receptors in the gut called mu-opioid receptors. By doing so, it regulates the activity of smooth muscle cells in the intestines, reducing their sensitivity and improving intestinal motility. It also stimulates the release of digestive enzymes, which can improve digestion and reduce symptoms such as bloating and discomfort.

Safety:

Trimebutine Base is generally considered safe when used as directed. However, like all medications, it may cause side effects in some people. It is not recommended for certain patients, such as those who have a history of allergic reactions or liver disease. It should also be used with caution in people with kidney disease, pregnancy, or lactation.

Side Effects:

Common side effects of Trimebutine Base include drowsiness, dry mouth, and headache. Rare but serious side effects may include allergic reactions, liver damage, and irregular heart rate. Patients who experience any of these symptoms should seek immediate medical attention.

Dosing Information:

The recommended dose of Trimebutine Base depends on the condition being treated and the individual patient's response to the medication. For irritable bowel syndrome and functional dyspepsia, the usual dose is 100-200 mg taken orally three times daily before meals. The duration of treatment varies depending on the severity of the symptoms.

Conclusion:

Trimebutine Base is a medication used to treat gastrointestinal disorders such as irritable bowel syndrome and functional dyspepsia. It works by regulating the movement of the digestive tract and reducing symptoms such as abdominal pain, bloating, and constipation. While it is generally safe and effective, it may cause side effects in some patients and is not recommended for certain populations. If you have any questions about Trimebutine Base or its use, please consult your healthcare provider

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code